Dr. Havranek-Kosicek, previously Director of Finance and Control for the DSM Pharma Chemicals business unit of DSM Pharmaceutical Products, the pharmaceutical contract manufacturing and technology organization of Royal DSM N.V. (NYSE, Euronext: DSM KON), has been appointed CFO of the entire business group. Dr. Havranek-Kosicek will report to Alexander R. Wessels, President and Chief Executive Officer of DSM Pharmaceutical Products.
Dr. Havranek-Kosicek has worked in business finance and control, investor relations and management for 14 years. Headquartered in Parsippany, NJ (USA), the DSM Pharmaceutical Products business group has a broad manufacturing platform for mammalian cell-based and microbial-based
biopharmaceuticals, R&D/formulation and proprietary technologies for biologics, active pharmaceutical ingredients and fermentation, covering
early stage drug development, clinical trials and commercial production as well as finished dosage form manufacturing across nine sites in the USA,
Europe and Australia.
Prior to joining DSM, Ms. Havranek-Kosicek held executive positions in financial control at Immofinanz AG, and was Managing Director of AUA
Beteiligungen GmbH and Vice President Corporate Subsidiaries and Investor Relations at Austrian Airlines. Ms. Havranek-Kosicek earned a Ph.D. in
Business Administration and a degree with a concentration in Controlling and Management from the University of Economics and Business
Administration of Vienna.